Key Points
- SVP Krista Davis sold 1,622 shares on Dec. 18 at $82.40 for $133,652.80, reducing her stake by 2.69% to 58,564 shares valued at about $4.83 million.
- Earnings beat: ANI reported $2.04 EPS vs. $1.74 expected and revenue of $227.81M (+53.6% YoY), set FY2025 guidance of $7.370–7.640 EPS, and carries a consensus "Moderate Buy" with an average target of $102.14.
- The stock trades in a 12‑month range of $52.74–$99.50, has a market cap of ~$1.86B and a P/E of ~50.8, and is ~76% owned by institutional investors.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $82.40, for a total value of $133,652.80. Following the transaction, the senior vice president directly owned 58,564 shares in the company, valued at approximately $4,825,673.60. The trade was a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
ANI Pharmaceuticals Price Performance
Shares of NASDAQ ANIP opened at $82.85 on Friday. ANI Pharmaceuticals, Inc. has a twelve month low of $52.74 and a twelve month high of $99.50. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The firm has a 50-day moving average of $86.70 and a two-hundred day moving average of $81.34. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 50.83 and a beta of 0.48.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million for the quarter, compared to the consensus estimate of $211.92 million. During the same period in the previous year, the firm earned $1.34 EPS. The business's revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ANIP. Global Alpha Capital Management Ltd. lifted its stake in ANI Pharmaceuticals by 17.2% in the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company's stock worth $56,251,000 after acquiring an additional 126,500 shares in the last quarter. UBS Group AG increased its holdings in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock valued at $54,032,000 after purchasing an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ANI Pharmaceuticals in the third quarter worth approximately $32,992,000. Rubric Capital Management LP lifted its position in shares of ANI Pharmaceuticals by 33.3% in the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company's stock worth $31,457,000 after purchasing an additional 85,745 shares in the last quarter. Finally, Balyasny Asset Management L.P. boosted its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock worth $26,211,000 after purchasing an additional 276,233 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ANIP has been the subject of several research reports. Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday. Guggenheim upped their target price on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a "buy" rating in a report on Monday, November 10th. JPMorgan Chase & Co. lifted their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 24th. HC Wainwright boosted their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a "buy" rating in a report on Wednesday, September 17th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a "hold" rating in a report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $102.14.
Get Our Latest Analysis on ANI Pharmaceuticals
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
